DTC Report: DTC Gets Smart
DTC Report: 10 Riskiest DTC Ads Ever
Rare Diseases: Orphans in Danger
Therapeutic Focus 2014: Respiratory
Headliner: Pharma's type "A" exec—and mentor
Non-Personal Promotion: A New Era in E-Sampling
Read the 2014 Game Changers digital edition
Skill Sets Live: Content Marketing for Healthcare
Boehringer Ingelheim says it is no longer pursuing an interferon-free combination of faldaprevir and deleobuvir.
Roche also announced first-quarter sales shrank 1%.
The latest IMS Institute for Healthcare Informatics assessment of 2013's prescription drug use shows that 2.3% of prescriptions account for 30% of a patient's out-of-pocket prescription costs.
New data from the International Liver Congress in London this past weekend showed strong efficacy for Gilead's Sovaldi and AbbVie's combo regimen when paired with ribavirin.
Nine things CMOs should consider when desiring to engage consumers who no longer want to give their attention to boring and scripted product descriptions.
Type-2 diabetes injection Tanzeum, also known as albiglutide, scored the approval Tuesday.
Healthcare insurers seek to curb diabetes costs with interventions that may include house calls.
The drugmaker says the therapeutic approach has a narrow treatment potential.
Click on the image above to see a gallery of images from the 2013 MM&M Awards dinner
The new MM&M e-book, "Oncology Marketing," is designed to serve as a companion for those in the business of communicating cancer products to all three stakeholders. It's packed with analysis, advice, insights and commentary to help navigate the terrain. Click here to access it.